From Nasdaq: 2025-02-21 13:51:00

Viatris (VTRS) is set to report Q4 and full-year 2024 results on Feb. 27, 2025. Revenues estimated at $3.60 billion, earnings at $0.57 per share. Factors include performance in Developed Markets, Emerging Markets, Japan, Australia, New Zealand, Greater China. Revenues estimates for each segment provided.

Viatris reports revenues from Developed Markets at $2.2 billion, Emerging Markets at $539 million, JANZ at $366 million, Greater China at $553 million. Brand business dominates portfolio. Operating expenses may rise due to investments. Shares down 13.2% in past year, mixed earnings surprise history, average surprise of 0.33%.

Model predicts no earnings beat for Viatris this quarter. Earnings ESP at -3.51%, Zacks Rank #4 (Sell). Consider other drug/biotech stocks like Pacira BioSciences (PCRX), Mirum Pharmaceuticals (MIRM), Viking Therapeutics (VKTX) with positive indicators. Viatris’ performance and predictions compared to other stocks in the industry.



Read more at Nasdaq: What’s in the Cards for Viatris Stock This Q4 Earnings?